These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
251 related articles for article (PubMed ID: 6248876)
1. Monoclonal antibody against a 250,000-dalton glycoprotein of Epstein-Barr virus identifies a membrane antigen and a neutralizing antigen. Hoffman GJ; Lazarowitz SG; Hayward SD Proc Natl Acad Sci U S A; 1980 May; 77(5):2979-83. PubMed ID: 6248876 [TBL] [Abstract][Full Text] [Related]
2. Identification of Epstein-Barr virus strain differences with monoclonal antibody to a membrane glycoprotein. Qualtiere LF; Chase R; Vroman B; Pearson GR Proc Natl Acad Sci U S A; 1982 Jan; 79(2):616-20. PubMed ID: 6176998 [TBL] [Abstract][Full Text] [Related]
3. Monoclonal antibodies against the major glycoprotein (gp350/220) of Epstein-Barr virus neutralize infectivity. Thorley-Lawson DA; Geilinger K Proc Natl Acad Sci U S A; 1980 Sep; 77(9):5307-11. PubMed ID: 6254073 [TBL] [Abstract][Full Text] [Related]
4. Monoclonal antibody specific for capsid antigen of Epstein-Barr virus. Takada K; Fujiwara S; Yano S; Osato T Med Microbiol Immunol; 1983; 171(4):225-31. PubMed ID: 6304479 [TBL] [Abstract][Full Text] [Related]
5. Characterization of cross-reacting antigens on the Epstein-Barr virus envelope and plasma membranes of producer cells. Thorley-Lawson DA Cell; 1979 Jan; 16(1):33-42. PubMed ID: 217544 [TBL] [Abstract][Full Text] [Related]
7. Peptides designed to spatially depict the Epstein-Barr virus major virion glycoprotein gp350 neutralization epitope elicit antibodies that block virus-neutralizing antibody 72A1 interaction with the native gp350 molecule. Tanner JE; Coinçon M; Leblond V; Hu J; Fang JM; Sygusch J; Alfieri C J Virol; 2015 May; 89(9):4932-41. PubMed ID: 25694592 [TBL] [Abstract][Full Text] [Related]
8. Inhibition of Epstein-Barr virus (EBV) release from P3HR-1 and B95-8 cell lines by monoclonal antibodies to EBV membrane antigen gp350/220. Sairenji T; Bertoni G; Medveczky MM; Medveczky PG; Nguyen QV; Humphreys RE J Virol; 1988 Aug; 62(8):2614-21. PubMed ID: 2839689 [TBL] [Abstract][Full Text] [Related]
9. Monoclonal antibodies to the latent membrane protein of Epstein-Barr virus reveal heterogeneity of the protein and inducible expression in virus-transformed cells. Rowe M; Evans HS; Young LS; Hennessy K; Kieff E; Rickinson AB J Gen Virol; 1987 Jun; 68 ( Pt 6)():1575-86. PubMed ID: 2438376 [TBL] [Abstract][Full Text] [Related]
10. Control of Epstein-Barr virus infection in vitro by T helper cells specific for virion glycoproteins. Adhikary D; Behrends U; Moosmann A; Witter K; Bornkamm GW; Mautner J J Exp Med; 2006 Apr; 203(4):995-1006. PubMed ID: 16549597 [TBL] [Abstract][Full Text] [Related]
11. Differential expression of Epstein-Barr virus membrane antigens defined with monoclonal antibodies. Yokochi T; Clark EA; Kimura Y Virology; 1986 Jan; 148(1):114-20. PubMed ID: 3002025 [TBL] [Abstract][Full Text] [Related]
12. Identification of a novel EBV-induced membrane glycoprotein of 43 kDa with H667 MAb. Sanchez-Pinel A; Bernad J; Rives H; Lapchine L; Icart J; Didier J Virology; 1991 Jan; 180(1):31-40. PubMed ID: 1845828 [TBL] [Abstract][Full Text] [Related]
13. A comparison of Epstein-Barr virus specific proteins expressed by three Epstein-Barr virus isolates using specific monoclonal antibodies. Tsai CH; Glaser R Intervirology; 1991; 32(6):376-82. PubMed ID: 1657827 [TBL] [Abstract][Full Text] [Related]
14. Production and characterization of monoclonal antibodies against the Epstein-Barr virus membrane antigen. Strnad BC; Schuster T; Klein R; Hopkins RF; Witmer T; Neubauer RH; Rabin H J Virol; 1982 Jan; 41(1):258-64. PubMed ID: 6177865 [TBL] [Abstract][Full Text] [Related]
15. Identification of an Epstein-Barr virus glycoprotein which is antigenically homologous to the varicella-zoster virus glycoprotein II and the herpes simplex virus glycoprotein B. Emini EA; Luka J; Armstrong ME; Keller PM; Ellis RW; Pearson GR Virology; 1987 Apr; 157(2):552-5. PubMed ID: 3029988 [TBL] [Abstract][Full Text] [Related]
16. Inhibition of Epstein-Barr virus (EBV) release from the P3HR-1 Burkitt's lymphoma cell line by a monoclonal antibody against a 200,000 dalton EBV membrane antigen. Sairenji T; Reisert PS; Spiro RC; Connolly T; Humphreys RE J Exp Med; 1985 May; 161(5):1097-111. PubMed ID: 2580934 [TBL] [Abstract][Full Text] [Related]
17. Human antibody titers to Epstein-Barr Virus (EBV) gp350 correlate with neutralization of infectivity better than antibody titers to EBV gp42 using a rapid flow cytometry-based EBV neutralization assay. Sashihara J; Burbelo PD; Savoldo B; Pierson TC; Cohen JI Virology; 2009 Sep; 391(2):249-56. PubMed ID: 19584018 [TBL] [Abstract][Full Text] [Related]
18. Purified Epstein-Barr virus Mr 340,000 glycoprotein induces potent virus-neutralizing antibodies when incorporated in liposomes. North JR; Morgan AJ; Thompson JL; Epstein MA Proc Natl Acad Sci U S A; 1982 Dec; 79(23):7504-8. PubMed ID: 6296836 [TBL] [Abstract][Full Text] [Related]
19. Production of monoclonal antibody to a late intracellular Epstein-Barr virus-induced antigen. Kishishita M; Luka J; Vroman B; Poduslo JF; Pearson GR Virology; 1984 Mar; 133(2):363-75. PubMed ID: 6324457 [TBL] [Abstract][Full Text] [Related]
20. Epstein-Barr virus strain- and group-specific antigenic determinants detected by monoclonal antibodies. Mueller-Lantzsch N; Georg-Fries B; Herbst H; zur Hausen H; Braun DG Int J Cancer; 1981 Sep; 28(3):321-7. PubMed ID: 6172392 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]